This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Karyopharm's (KPTI) Eltanexor Gets Orphan Drug Tag for MDS
by Zacks Equity Research
The FDA bestows an Orphan Drug status to Karyopharm's (KPTI) investigational candidate, eltanexor, for treating myelodysplastic syndromes.
Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of 11.11% and 9.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Geron (GERN) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron (GERN) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of 0.00% and 33.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Geron (GERN) Q2 Earnings Expected to Decline
by Zacks Equity Research
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron (GERN) Soars on Imetelstat Data for Myelofibrosis
by Zacks Equity Research
Geron (GERN) publishes data from the phase II IMbark study evaluating its lead pipeline candidate, imetelstat, for treating relapsed/refractory myelofibrosis. Stock rises.
Do Options Traders Know Something About Geron (GERN) Stock We Don't?
by Zacks Equity Research
Investors need to pay close attention to Geron (GERN) stock based on the movements in the options market lately.
Geron (GERN) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of -12.50% and 82.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Geron (GERN) Begins Phase III Myelofibrosis Study on Imetelstat
by Zacks Equity Research
Geron (GERN) is evaluating its lead pipeline candidate, imetelstat, in late-stage studies for refractory myelofibrosis and myelodysplastic syndromes.
Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron (GERN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Geron (GERN) delivered earnings and revenue surprises of -20.00% and 44.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
What's in the Cards for Enlivex (ENLV) This Earnings Season?
by Zacks Equity Research
Investors will be keen on pipeline updates when Enlivex Therapeutics (ENLV) reports results for the three months ending Sep 30, 2020.
Is a Disappointment in Store for Tilray's (TLRY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports third-quarter 2020 results.
Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day
by Zacks Equity Research
Qorvo, Nikola, BMY, MyoKardia and Geron as Zacks Bull and Bear of the Day
Is a Disappointment in Store for Zosano (ZSAN) Q3 Earnings?
by Zacks Equity Research
Investors will be keen on updates on Qtrypta when Zosano (ZSAN) reports Q3 results.
Mylan (MYL) to Report Q3 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors will look forward to regular top and bottom-line numbers and updates on the merger with Upjohn, when Mylan (MYL) reports Q3 results.
Is a Beat in the Cards for Bristol-Myers' (BMY) Q3 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports third-quarter 2020 results.
What's in the Cards for Regeneron's (REGN) Q3 Earnings?
by Zacks Equity Research
Investors will focus on the performance of Eylea and Dupixent along with other pipeline updates when Regeneron (REGN) reports third-quarter 2020 results.
Incyte (INCY) to Post Q3 Earnings: Will Jakafi Drive Results?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with pipeline updates, when Incyte (INCY) reports third-quarter 2020 results.
Geron (GERN) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Geron (GERN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron (GERN) Looks Good: Stock Adds 6.5% in Session
by Zacks Equity Research
Geron (GERN) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Will Geron (GERN) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Geron Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Geron has been struggling lately, but the selling pressure may be coming to an end soon
Geron Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Geron has been struggling lately, but the selling pressure may be coming to an end soon.
Is Geron (GERN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (GERN) Outperforming Other Medical Stocks This Year?